Item 7.01. Regulation FD Disclosure.
As previously announced, TYME will be presenting its poster "Oral SM-88 plus MPS: an effective yet less toxic treatment option in second-line advanced pancreatic cancer? Final Phase II/III study results" at the 2022American Society of Clinical Oncology ("ASCO") Gastrointestinal Cancer Symposium, which is being held both online and in person inSan Francisco, CA fromJanuary 20-22, 2022 . TYME's presentation is scheduled to take place at3:05 p.m. Eastern Standard Time onJanuary 21, 2022 . In the poster, TYME presents the final results of Part 1 of its multicenter, prospective open-label trial, TYME-88-Panc, studying SM-88 in late-stage patients with advanced pancreatic cancer. As previously disclosed, TYME has discontinued the TYME-88-Panc trial and, accordingly, will not be presenting any further results, including results of Part 2 of the Study. Additional information on the meeting can be found on the ASCO 2022 Gastrointestinal Cancers Symposium website at https://conferences.asco.org/gi/program. Information on ASCO's website is not incorporated by reference herein. A copy of the poster is available on our website at https://tymeinc.com/data-publications/scientific-presentations/default.aspx?_ga=2.14989942.1910725466.1642085084-49066985.1641324922.
--------------------------------------------------------------------------------
© Edgar Online, source